Optimizing Intranasal Drug Delivery

At another stop on Pharma's Almanac's Road to 50 States trip, Don Turner, Chairman and CEO at Neosinus Health, talks to Nigel about the great potential of intranasal drug delivery and how Neosinus Health has used physiology, anatomy, and physics to optimize the delivery method.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Neosinus Health

NEOSINUS is a drug development platform company that has commercialized a fully integrated Platform for optimizing drug delivery and health outcomes.  The core platform is designed to optimize the delivery of medications to essential drug pathways and overcome physiological barriers that currently impede high potential drugs.

The company has developed a platform that will transform the delivery and effectiveness of drugs for mental health, neurological disorders, respiratory illnesses, immune system disorders, and more through strategic out-licensing partnerships and internal clinical development programs.

The company is playing a leadership role in integrating high-potential drugs, emerging nanotechnologies, and a new class of drugs that will address the largest global health burden and deliver new therapies that have been unattainable for many decades.